CIPLA Stock Overview
Engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for CIPLA from our risk checks.
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Cipla Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,454.10 |
| 52 Week High | ₹1,702.05 |
| 52 Week Low | ₹1,192.10 |
| Beta | 0.36 |
| 11 Month Change | -6.36% |
| 3 Month Change | -12.26% |
| 1 Year Change | 19.53% |
| 33 Year Change | 62.34% |
| 5 Year Change | 210.84% |
| Change since IPO | 44,961.36% |
Recent News & Updates
We Ran A Stock Scan For Earnings Growth And Cipla (NSE:CIPLA) Passed With Ease
Dec 07
Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 01Recent updates
We Ran A Stock Scan For Earnings Growth And Cipla (NSE:CIPLA) Passed With Ease
Dec 07Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 01Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk
Sep 29Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00
Jun 06Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's
May 21Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
May 14With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case
May 03Is Cipla (NSE:CIPLA) Using Too Much Debt?
Feb 14Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Jan 26Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely
Jan 08Shareholder Returns
| CIPLA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.1% | -0.8% | 1.3% |
| 1Y | 19.5% | 45.0% | 26.9% |
Return vs Industry: CIPLA underperformed the Indian Pharmaceuticals industry which returned 45% over the past year.
Return vs Market: CIPLA underperformed the Indian Market which returned 26.9% over the past year.
Price Volatility
| CIPLA volatility | |
|---|---|
| CIPLA Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: CIPLA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: CIPLA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1935 | 27,764 | Umang Vohra | www.cipla.com |
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry.
Cipla Limited Fundamentals Summary
| CIPLA fundamental statistics | |
|---|---|
| Market cap | ₹1.17t |
| Earnings (TTM) | ₹44.75b |
| Revenue (TTM) | ₹262.64b |
26.2x
P/E Ratio4.5x
P/S RatioIs CIPLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CIPLA income statement (TTM) | |
|---|---|
| Revenue | ₹262.64b |
| Cost of Revenue | ₹89.70b |
| Gross Profit | ₹172.94b |
| Other Expenses | ₹128.19b |
| Earnings | ₹44.75b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 55.41 |
| Gross Margin | 65.85% |
| Net Profit Margin | 17.04% |
| Debt/Equity Ratio | 0.6% |
How did CIPLA perform over the long term?
See historical performance and comparison